Cogent Biosciences Announces Participation in the Citi Biopharma Conference
Cogent Biosciences (Nasdaq: COGT), a biotechnology company developing precision therapies, announced its participation in the Citi Biopharma Back to School Conference on September 3, 2025 at 9:00 a.m. ET. A live webcast will be available on the company's investor relations website, with a replay accessible for 30 days.
Additionally, the company granted inducement equity awards to two new employees, consisting of options to purchase 54,500 shares of common stock. The options have a 10-year term and a four-year vesting schedule, with 25% vesting after one year and the remainder monthly over 36 months.
Cogent Biosciences (Nasdaq: COGT), una societ脿 biotecnologica che sviluppa terapie di precisione, ha annunciato la propria partecipazione al Citi Biopharma Back to School Conference il 3 settembre 2025 alle 9:00 ET. Una diretta webcast sar脿 disponibile sul sito IR della societ脿, con la registrazione disponibile in replay per 30 giorni.
Inoltre, l'azienda ha assegnato premi azionari di incentivo a due nuovi dipendenti, costituiti da opzioni per l'acquisto di 54.500 azioni ordinarie. Le opzioni hanno una durata di 10 anni e seguono un piano di maturazione di quattro anni: il 25% matura dopo un anno, il resto viene maturato mensilmente nei successivi 36 mesi.
Cogent Biosciences (Nasdaq: COGT), una compa帽铆a biotecnol贸gica que desarrolla terapias de precisi贸n, anunci贸 su participaci贸n en el Citi Biopharma Back to School Conference el 3 de septiembre de 2025 a las 9:00 a. m. ET. Habr谩 una retransmisi贸n en directo disponible en la web de relaciones con inversores de la compa帽铆a, y la grabaci贸n quedar谩 accesible en replay durante 30 d铆as.
Adem谩s, la compa帽铆a otorg贸 premios de capital por incentivos a dos nuevos empleados, consistentes en opciones para comprar 54.500 acciones ordinarias. Las opciones tienen un plazo de 10 a帽os y un calendario de adquisici贸n de derechos de cuatro a帽os: el 25% se adquiere tras un a帽o y el resto se adquiere mensualmente durante los siguientes 36 meses.
Cogent Biosciences (Nasdaq: COGT)電� 鞝曤皜 旃橂鞝滊ゼ 臧滊皽頃橂姅 氚旍澊鞓ろ厡韥� 須岇偓搿�, 2025雲� 9鞗� 3鞚� 鞓れ爠 9鞁�(ET)鞐� 鞐措Μ電� Citi Biopharma Back to School Conference鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓鞚� 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼鞐愳劀 靸濎瓿� 鞗轨簮鞀ろ姼臧� 鞝滉车霅橂┌, 鞛儩 鞓侅儊鞚� 30鞚� 霃欖晥 鞚挫毄頃� 靾� 鞛堨姷雼堧嫟.
霕愴暅 須岇偓電� 霊� 氇呾潣 鞁犾瀰 歆侅洂鞐愱矊 鞙犾澑順� 欤检嫕 氤挫儊鞚� 攵�鞐枅鞙茧┌, 鞚措姅 54,500欤�鞚� 氤错喌欤茧ゼ 毵れ垬頃� 靾� 鞛堧姅 鞓奠厴鞙茧 甑劚霅橃柎 鞛堨姷雼堧嫟. 鞓奠厴鞚� 鞙犿毃旮瓣皠鞚� 10雲勳澊瓿�, 甓岆Μ頇曥爼(氩犾姢韺�)鞚� 4雲� 鞀れ紑欷勲 霅橃柎 鞛堨溂氅� 1雲� 頉� 25%臧� 頇曥爼霅橁碃 雮橂ǜ歆�電� 頄ロ泟 36臧滌洈鞐� 瓯胳硱 毵れ洈 頇曥爼霅╇媹雼�.
Cogent Biosciences (Nasdaq: COGT), une soci茅t茅 de biotechnologie d茅veloppant des th茅rapies de pr茅cision, a annonc茅 sa participation au Citi Biopharma Back to School Conference le 3 septembre 2025 脿 9h00 ET. Une diffusion en direct sera disponible sur le site relations investisseurs de la soci茅t茅, et la rediffusion restera accessible pendant 30 jours.
Par ailleurs, la soci茅t茅 a accord茅 des attributions d'actions d'incitation 脿 deux nouveaux employ茅s, consistant en options d'achat de 54 500 actions ordinaires. Les options ont une dur茅e de 10 ans et un calendrier d'acquisition sur quatre ans : 25 % acqui猫rent apr猫s un an, le reste s'acquiert mensuellement sur les 36 mois suivants.
Cogent Biosciences (Nasdaq: COGT), ein Biotechnologieunternehmen, das Pr盲zisionstherapien entwickelt, gab seine Teilnahme an der Citi Biopharma Back to School Conference am 3. September 2025 um 9:00 Uhr ET bekannt. Ein Live-Webcast wird auf der Investor-Relations-Website des Unternehmens verf眉gbar sein, die Aufzeichnung wird 30 Tage abrufbar bleiben.
Zudem hat das Unternehmen Anreizaktienzuteilungen an zwei neue Mitarbeiter gew盲hrt, bestehend aus Optionen zum Kauf von 54.500 Aktien des Stammkapitals. Die Optionen haben eine Laufzeit von 10 Jahren und eine vierj盲hrige Vesting-Regelung: 25 % vesten nach einem Jahr, der Rest vestet monatlich 眉ber die folgenden 36 Monate.
- None.
- None.
WALTHAM, Mass. and BOULDER, Colo., Aug. 26, 2025 (GLOBE NEWSWIRE) -- 听(狈补蝉诲补辩: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in a fireside chat at the Citi Biopharma Back to School Conference on Wednesday, September 3, 2025 at 9:00 a.m. ET.
A live webcast will be available on the Investors & Media page of Cogent鈥檚 website at . A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.
Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cogent also announced today that the Compensation Committee of Cogent鈥檚 Board of Directors, made up entirely of independent directors, approved the grants of 鈥渋nducement鈥� equity awards to two new employees under the company鈥檚 2020 Inducement Plan with a grant date of August 25, 2025. The awards were approved in accordance with Listing Rule 5635(c)(4) of the corporate governance rules of the Nasdaq Stock Market. The employees received, in the aggregate, nonqualified options to purchase 54,500 shares of Cogent common stock. Each option has a 10-year term, an exercise price equal to the closing price of Cogent鈥檚 common stock on the grant date, and a four-year vesting schedule with
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2/3 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3K伪 and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at聽. Follow Cogent Biosciences on social media:聽聽(formerly known as Twitter)聽and聽. Information that may be important to investors will be routinely posted on our website and聽.
Contact:
Christi Waarich
Senior Director, Investor Relations
617-830-1653
FAQ
When is Cogent Biosciences (COGT) presenting at the Citi Biopharma Conference 2025?
How can investors access Cogent Biosciences' (COGT) Citi conference presentation?
What inducement grants did Cogent Biosciences (COGT) announce in August 2025?
What is Cogent Biosciences' (COGT) main business focus?
